Drugs News and Research

RSS

Bariatric surgery offers greater long-term health protection for seniors than GLP-1 drugs

Metabolic and bariatric surgery offers significantly greater long-term protection against heart attack, stroke and death than widely-used GLP-1 drugs in older adults with obesity and diabetes, according to new real-world analysis study presented today at the annual meeting of the American Society for Metabolic and Bariatric Surgery.

6 May 2026

Bariatric surgery outperforms GLP-1 medications for obesity disease remission

Metabolic and bariatric surgery delivers significantly greater weight loss and higher rates of obesity-related disease remission than glucagon-like peptide-1 receptor agonists (GLP-1s), according to one of the largest and most comprehensive real-world comparisons of the two treatments.

6 May 2026

Organic lithium salts may affect many cellular level changes in Alzheimer's disease

Lithium chloride may affect many cellular level changes in Alzheimer's disease, a new study from the University of Eastern Finland (UEF) shows.

6 May 2026

New inhibitor design provides a blueprint for effective malaria treatments

Researchers from the Universities of Bath and Leeds (UK) have made a significant advance in the fight against malaria by uncovering a promising new potential target for drug discovery.

6 May 2026

USF researchers develop AI framework to predict immune system responses

Artificial intelligence is increasingly being used to help scientists accelerate drug discovery and search for new treatments.

6 May 2026

Calla Lily Clinical Care doses first patients in clinical trial for intravaginal drug delivery platform for threatened miscarriage

Calla Lily Clinical Care, a women’s health-focused medical technology company, today announced dosing of the first patients in the FREEDOM clinical trial.

6 May 2026

Popular GLP-1 drugs significantly reduce major cardiovascular events,

Researchers evaluate the long-term cardiovascular safety and efficacy of GLP-1RAs in high-risk populations.

6 May 2026

Non-destructive technique enables repeated transcriptome analysis in living cells

Normally, cells must be lysed for a so-called transcriptome analysis - which reveals which genes are currently being expressed - making repeated measurements on the same cells impossible.

5 May 2026

New method matures lab-grown heart cells for better research

Researchers at the University of Toronto's Institute of Biomedical Engineering have developed a new method to mature lab-grown heart cells, so they more closely resemble adult human heart tissue.

5 May 2026

AI creates detailed map of fat and muscle distribution to predict major health risks

Researchers used AI to analyze whole-body MRI scans from more than 66,000 participants to create the most detailed reference map to date of how fat and muscle are distributed in the human body across age, sex and height.

5 May 2026

U.S. bariatric surgery rates drop significantly amid GLP-1 surge

The number of metabolic and bariatric surgery procedures in the United States dropped below 200,000 in 2024 for the first time since 2020, a more than 20% decline from the prior year, according to new research presented today at the annual scientific meeting of the American Society for Metabolic and Bariatric Surgery.

5 May 2026

Bariatric surgery costs significantly less than GLP-1 drugs over two years

A new real-world analysis of more than 90,000 patients with obesity and type 2 diabetes finds metabolic and bariatric surgery is costs significantly less than weekly injections of GLP-1 drugs over a two-year period, according to a new research presented today at the annual scientific meeting of the American Society for Metabolic and Bariatric Surgery.

5 May 2026

Specific health labels may better motivate reduced alcohol consumption

Although the United States requires a warning label on alcoholic beverages, alcohol-related deaths have risen steadily over the past two decades.

5 May 2026

Machine learning study identifies distinct subtypes of Parkinson's disease

A new study led by researchers from VIB and KU Leuven shows that Parkinson's disease can be divided into distinct subtypes, helping explain why a single treatment does not work for all patients.

5 May 2026

GLP-1 drugs combined with surgery yield superior weight loss results

People who begin obesity treatment with glucagon-like peptide-1 receptor agonists (GLP-1s) and then undergo metabolic and bariatric surgery achieve substantially greater weight loss than with the medications alone, according to new research presented today at the annual meeting of the American Society for Metabolic and Bariatric Surgery.

5 May 2026

New molecular framework paves the way for targeted Parkinson’s therapeutic interventions

A new study led by researchers from VIB and KU Leuven shows that Parkinson's disease can be divided into distinct subtypes, helping explain why a single treatment does not work for all patients. Using an machine-learning-driven analysis, the team identified two main groups and five subgroups of the disease, marking an important step toward more personalized therapies. The findings were recently published in Nature Communications.

5 May 2026

Global MS initiative opens applications for research data access

The International Progressive MS Alliance announces the MS Clinical and Imaging Data Resource (MS CIDR) is now accepting applications for data access.

4 May 2026

Study highlights stigma surrounding popular GLP-1 weight loss drugs

Glucagonlike peptide-1 (GLP-1) medications have taken over the national conversation around weight loss.

4 May 2026

Protective brain pathway may slow Parkinson’s progression in females

Scientists have identified a protective brain pathway that may help slow the progression of Parkinson's disease by strengthening the brain's own dopamine‑producing neurons, but the positive effect was only observed in females.

4 May 2026

NIH awards $3.9 million grant to develop a non-opioid pain treatment

The National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health (NIH), has awarded a $3.9 million grant to a multi-institutional team led by scientists at Sanford Burnham Prebys Medical Discovery Institute to develop a non-opioid pain therapeutic and advance it into a Phase 1 clinical trial.

4 May 2026